Status:
COMPLETED
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Geographic Atrophy
Age-related Macular Degeneration
Eligibility:
All Genders
55+ years
Phase:
PHASE2
Brief Summary
This study was conducted in two parts; Part A and Part B: Part B was initially planned to include two cohorts. Cohort 2 was cancelled following an interim analysis for efficacy in Part A of the study,...
Eligibility Criteria
Inclusion
- Diagnosis of AMD if enrolled in Part B of study
- Geographic atrophy in at least one eye if enrolled in Part A of study
- ETDRS best corrected visual acuity of 60 letters or worse (\~≤ 20/63)
Exclusion
- Retinal disease other than AMD
- History of choroidal neovascularization
- Severe cataract
- History of infectious uveitis or endophthalmitis
- Eye surgery in the non-study eye within 30 days prior to study
- Eye surgery or IVT injection in the study eye within 90 days prior to study
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
January 25 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 24 2015
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT01527500
Start Date
January 25 2012
End Date
June 24 2015
Last Update
January 5 2021
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Phoenix, Arizona, United States, 85014
2
Novartis Investigative Site
Phoenix, Arizona, United States, 85020
3
Novartis Investigative Site
Tucson, Arizona, United States, 85704-5614
4
Novartis Investigative Site
Beverly Hills, California, United States, 90211